Pfizer announced Tuesday that a large international study found vaccinating moms-to-be was nearly 82% effective at preventing severe cases of RSV in their babies’ most vulnerable first 90 days of life.
Pfizer said the vaccine, which is given to pregnant people to protect infants from birth, was safe, well-tolerated and had an efficacy of nearly 70% against severe respiratory illness from RSV in the first six months of life.
Pfizer says it has enough promising data on its respiratory syncytial virus, or RSV, vaccine designed to protect newborns that it will end enrollment in the study and submit for US Food and Drug Administration approval by the end of the year.
Pfizer reports that a large international study found vaccinating moms-to-be was nearly 82% effective at preventing severe cases of RSV in their babies’ most vulnerable first 90 days of life.
Pfizer announced an experimental vaccine that, when administered during pregnancy, would protect infants from severe illness for up to six months of life.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
New RSV vaccine given in pregnancy protects newborns from illness, Pfizer says | Since Then
